Sources and signals regulating type i interferon production: Lessons learned from cytomegalovirus

Journal of Interferon and Cytokine Research

Volumn 31, Issue 2, 2011, Pages 211-218

  Verma, Shilpi ^a   Benedict, Chris A ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; CYTOKINE; INTERFERON; INTERFERON TYPE 1; LYMPHOTOXIN; LYMPHOTOXIN ALPHA RECEPTOR; LYMPHOTOXIN BETA RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; INNATE IMMUNITY; MOUSE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; STROMA;

ANIMALS; B-LYMPHOCYTES; CYTOMEGALOVIRUS; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER; LYMPHOTOXIN BETA RECEPTOR; SIGNAL TRANSDUCTION; STROMAL CELLS;

CYTOMEGALOVIRUS; HERPESVIRIDAE;

EID: 79951833541     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0118     Document Type: Review

References (70)

1. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. 2010. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464(7286):302-305.
2. Banks TA, Rickert S, Benedict CA, Ma L, Ko M, Meier J, Ha W, Schneider K, Granger SW, Turovskaya O, Elewaut D, Otero D, French AR, Henry SC, Hamilton JD, Scheu S, Pfeffer K, Ware CF. 2005. A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol 174(11):7217-7225. (Pubitemid 40705690)
3. Benedict CA, Banks TA, Senderowicz L, Ko M, Britt WJ, Angulo A, Ghazal P, Ware CF. 2001. Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus detente. Immunity 15(4):617-626. (Pubitemid 33016446)
4. Benedict CA, De Trez C, Schneider K, Ha S, Patterson G, Ware CF. 2006. Specific remodeling of splenic architecture by cytomegalovirus. PLoS Pathog 2(3):e16.
5. Beutler B, Georgel P, Rutschmann S, Jiang Z, Croker B, Crozat K. 2005. Genetic analysis of innate resistance to mouse cytomegalovirus (MCMV). Brief Funct Genomic Proteomic 4(3): 203-213. (Pubitemid 43055802)
6. Browne EP, Wing B, Coleman D, Shenk T. 2001. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. J Virol 75:12319-12330. (Pubitemid 33115904)
7. Chong KT, Gresser I, Mims CA. 1983. Interferon as a defence mechanism in mouse cytomegalovirus infection. J Gen Virol 64 (Pt 2):461-464. (Pubitemid 13115973)
8. Dalod M, Hamilton T, Salomon R, Salazar-Mather TP, Henry SC, Hamilton JD, Biron CA. 2003. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J Exp Med 197(7):885-898. (Pubitemid 36437865)
9. Dalod M, Salazar-Mather TP, Malmgaard L, Lewis C, Asselin- Paturel C, Briere F, Trinchieri G, Biron CA. 2002. Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 195(4):517-528. (Pubitemid 34461304)
10. DeFilippis VR. 2007. Induction and evasion of the type I interferon response by cytomegaloviruses. Adv Exp Med Biol 598:309-324.
11. DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Fruh K. 2010. Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. J Virol 84(1):585-598.
12. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF, Green DR. 2002. The lymphotoxinbeta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17(4):525-535. (Pubitemid 35223540)
13. Ettinger R, Browning JL, Michie SA, van Ewijk W, McDevitt HO. 1996. Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-b receptor-IgG1 fusion protein. Proc Natl Acad Sci USA 93: 13102-13107. (Pubitemid 26382776)
14. Fletcher AL, Lukacs-Kornek V, Reynoso ED, Pinner SE, Bellemare- Pelletier A, Curry MS, Collier AR, Boyd RL, Turley SJ. 2010. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J Exp Med 207(4):689-697.
15. Grundy JE, Trapman J, Allan JE, Shellam GR, Melief CJ. 1982. Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun 37(1):143-150. (Pubitemid 12095194)
16. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M. 2009. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16(4):295-308.
17. Hsu KM, Pratt JR, Akers WJ, Achilefu SI, Yokoyama WM. 2009. Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J Gen Virol 90 (Pt 1):33-43.
18. Ishikawa H, Barber GN. 2008. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455(7213):674-678.
19. Iversen AC, Norris PS, Ware CF, Benedict CA. 2005. Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta. J Immunol 175(11):7568-7574. (Pubitemid 41713456)
20. Jarvis MA, Borton JA, Keech AM, Wong J, Britt WJ, Magun BE, Nelson JA. 2006. Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation. J Virol 80(11):5588-5598.
21. Kaiser WJ, Upton JW, Mocarski ES. 2008. Receptor-interacting protein homotypic interaction motif-dependent control of NFkappa B activation via the DNA-dependent activator of IFN regulatory factors. J Immunol 181(9):6427-6434.
22. Katakai T, Hara T, Sugai M, Gonda H, Shimizu A. 2004. Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J Exp Med 200(6):783-795. (Pubitemid 39299464)
23. Kern ER. 2006. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res 71(2-3):164-171.
24. Kern ER, Olsen GA, Overall JC, Jr., Glasgow LA. 1978. Treatment of a murine cytomegalovirus infection with exogenous interferon, polyinosinic- polycytidylic acid, and polyinosinicpolycytidylic acid-poly-L-lysine complex. Antimicrob Agents Chemother 13(2):344-346. (Pubitemid 8281005)
25. Kraal G, Mebius R. 2006. New insights into the cell biology of the marginal zone of the spleen. Int Rev Cytol 250:175-215. (Pubitemid 44067206)
26. Lenac T, Arapovic J, Traven L, Krmpotic A, Jonjic S. 2008. Murine cytomegalovirus regulation of NKG2D ligands. Med Microbiol Immunol 197(2):159-166.
27. Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz B, Cyster JG, Luther SA. 2007. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol 8(11):1255-1265. (Pubitemid 350011765)
28. Loewendorf A, Benedict CA. 2010. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med 267:483-501.
29. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM. 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206(7):1589-1602.
30. Mackay F, Majeau GR, Lawton P, Hochman PS, Browning JL. 1997. Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. Eur J Immunol 27(8):2033-2042. (Pubitemid 27346021)
31. Maniatis T, Falvo JV, Kim TH, Kim TK, Lin CH, Parekh BS, Wathelet MG. 1998. Structure and function of the interferonbeta enhanceosome. Cold Spring Harb Symp Quant Biol 63:609-620.
32. Marshall EE, Geballe AP. 2009. Multifaceted evasion of the interferon response by cytomegalovirus. J Interferon Cytokine Res 29(9):609-619.
33. Mebius RE, Kraal G. 2005. Structure and function of the spleen. Nat Rev Immunol 5(8):606-616. (Pubitemid 41113192)
34. Mercer JA, Wiley CA, Spector DH. 1988. Pathogenesis of murine cytomegalovirus infection: identification of infected cells in the spleen during acute and latent infections. J Virol 62:987-997. (Pubitemid 18068658)
35. Mueller SN, Germain RN. 2009. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat Rev Immunol 9(9):618-629.
36. Mueller SN, Hosiawa-Meagher KA, Konieczny BT, Sullivan BM, Bachmann MF, Locksley RM, Ahmed R, Matloubian M. 2007. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 317(5838):670-674. (Pubitemid 47229967)
37. Nakano H, Oshima H, Chung W, Williams-Abbott L, Ware C, Yagita H, Okumura K. 1996. TRAF5, an activator of NF-kB and putative signal transducer for the lymphotoxin-b receptor. J Biol Chem 271:14661-14664. (Pubitemid 26194937)
38. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, Caligiuri MA, Durbin JE, Biron CA. 2002. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169(8):4279-4287. (Pubitemid 35178200)
39. Orange JS, Biron CA. 1996. Characterization of early IL-12, IFNalpha beta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol 156(12):4746-4756. (Pubitemid 26174459)
40. Orange JS, Wang B, Terhorst C, Biron CA. 1995. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med 182(4):1045-1056.
41. Osborn JE, Medearis DN, Jr. 1966. Studies of relationship between mouse cytomegalovirus and interferon. Proc Soc Exp Biol Med 121(3):819-824.
42. Pereira L, Maidji E, McDonagh S, Tabata T. 2005. Insights into viral transmission at the uterine-placental interface. Trends Microbiol 13(4):164-174. (Pubitemid 40463318)
43. Pichlmair A, Reis e Sousa C. 2007. Innate recognition of viruses. Immunity 27(3):370-383. (Pubitemid 47418682)
44. Powers C, Fruh K. 2008. Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol 197(2): 109-115.
45. Randall TD, Carragher DM, Rangel-Moreno J. 2008. Development of secondary lymphoid organs. Annu Rev Immunol 26:627-650. (Pubitemid 351600387)
46. Rebsamen M, Heinz LX, Meylan E, Michallet MC, Schroder K, Hofmann K, Vazquez J, Benedict CA, Tschopp J. 2009. DAI/ ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Rep 10(8): 916-922.
47. Sacher T, Podlech J, Mohr CA, Jordan S, Ruzsics Z, Reddehase MJ, Koszinowski UH. 2008. The major virus-producing cell type during murine cytomegalovirus infection, the hepatocyte, is not the source of virus dissemination in the host. Cell Host Microbe 3(4):263-272. (Pubitemid 351494715)
48. Sanjo H, Zajonc DM, Braden R, Norris PS, Ware CF. 2010. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. J Biol Chem 285(22):17148-17155.
49. Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, Degli-Esposti MA. 2007. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol 85(1):46-54. (Pubitemid 46067321)
50. Scandella E, Bolinger B, Lattmann E, Miller S, Favre S, Littman DR, Finke D, Luther SA, Junt T, Ludewig B. 2008. Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat Immunol 9(6):667-675. (Pubitemid 351712637)
51. Schilte C, Couderc T, Chretien F, Sourisseau M, Gangneux N, Guivel-Benhassine F, Kraxner A, Tschopp J, Higgs S, Michault A, Arenzana-Seisdedos F, Colonna M, Peduto L, Schwartz O, Lecuit M, Albert ML. 2010. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med 207(2):429-442.
52. Schneider K, Loewendorf A, De Trez C, Fulton J, Rhode A, Shumway H, Ha S, Patterson G, Pfeffer K, Nedospasov SA, Ware CF, Benedict CA. 2008. Lymphotoxin-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus. Cell Host Microbe 3(2):67-76. (Pubitemid 351201786)
53. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. 2006. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43(9): 1143-1151. (Pubitemid 44632796)
54. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, Taniguchi T. 2007. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448(7152): 501-505. (Pubitemid 47123520)
55. Takeuchi O, Akira S. 2008. MDA5/RIG-I and virus recognition. Curr Opin Immunol 20(1):17-22.
56. Takeuchi O, Akira S. 2009. Innate immunity to virus infection. Immunol Rev 227(1):75-86.
57. Tamura T, Yanai H, Savitsky D, Taniguchi T. 2008. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26:535-584. (Pubitemid 351600385)
58. Taylor RT, Bresnahan WA. 2005. Human cytomegalovirus immediate-early 2 gene expression blocks virus-induced beta interferon production. J Virol 79(6):3873-3877. (Pubitemid 40327977)
59. Taylor RT, Bresnahan WA. 2006. Human cytomegalovirus immediate- early 2 protein IE86 blocks virus-induced chemokine expression. J Virol 80(2):920-928. (Pubitemid 43062904)
60. Thanos D, Maniatis T. 1995. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83(7):1091-1100. (Pubitemid 26007801)
61. Tomei AA, Siegert S, Britschgi MR, Luther SA, Swartz MA. 2009. Fluid flow regulates stromal cell organization and CCL21 expression in a tissue-engineered lymph node microenvironment. J Immunol 183(7):4273-4283.
62. Tumanov AV, Grivennikov SI, Shakhov AN, Rybtsov SA, Koroleva EP, Takeda J, Nedospasov SA, Kuprash DV. 2003a. Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunol Rev 195:106-116. (Pubitemid 37153457)
63. Tumanov AV, Kuprash DV, Nedospasov SA. 2003b. The role of lymphotoxin in development and maintenance of secondary lymphoid tissues. Cytokine Growth Factor Rev 14(3-4): 275-288. (Pubitemid 36693147)
64. Tyznik AJ, Tupin E, Nagarajan NA, Her MJ, Benedict CA, Kronenberg M. 2008. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol 181(7):4452-4456.
65. VanArsdale TL, VanArsdale SL, Force WR, Walter BN, Mosialos G, Kieff E, Reed JC, Ware CF. 1997. Lymphotoxin-b receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kB. Proc Natl Acad Sci USA 94:2460-2465. (Pubitemid 27136897)
66. Varani S, Frascaroli G, Landini MP, Soderberg-Naucler C. 2009. Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity. Rev Med Virol 19(3):131-145.
67. Ware CF. 2005. NETWORK COMMUNICATIONS: Lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23: 787-819. (Pubitemid 40563185)
68. Wesley JD, Tessmer MS, Chaukos D, Brossay L. 2008. NK celllike behavior of Valpha14i NK T cells during MCMV infection. PLoS Pathog 4(7):e1000106.
69. Yanai H, Savitsky D, Tamura T, Taniguchi T. 2009. Regulation of the cytosolic DNA-sensing system in innate immunity: a current view. Curr Opin Immunol 21(1):17-22.
70. Zindl CL, Kim TH, Zeng M, Archambault AS, Grayson MH, Choi K, Schreiber RD, Chaplin DD. 2009. The lymphotoxin LTalpha(1)beta(2) controls postnatal and adult spleen marginal sinus vascular structure and function. Immunity 30(3):408-420.